SPECT- and Fluorescence Image–Guided Surgery Using a Dual-Labeled Carcinoembryonic Antigen–Targeting Antibody
- 30 June 2014
- journal article
- Published by Society of Nuclear Medicine in Journal of Nuclear Medicine
- Vol. 55 (9), 1519-1524
- https://doi.org/10.2967/jnumed.114.142141
Abstract
Intraoperative visualization techniques promise to significantly improve the detection and resection of tumors. In this study, we used an anti-carcinoembryonic antigen (CEA) antibody (MN-14) tagged with both a radiolabel ((111)In) and a fluorophore (IRDye 800CW) for radionuclide detection and intraoperative fluorescence imaging, respectively. For this purpose, we prepared and characterized the dual-labeled antibody (111)In-diethylenetriaminepentaacetic acid (DTPA)-MN-14-IRDye 800CW and performed 4 studies on mice with subcutaneous and intraperitoneal CEA-expressing tumors: a dose escalation study to determine the optimal MN-14 protein dose, a biodistribution study comparing dual-labeled MN-14 and radiolabeled MN-14, a study to determine the optimal time for SPECT and fluorescence imaging after injection of dual-labeled MN-14, and finally a SPECT and fluorescence image-guided surgery study using this dual-labeled antibody. The optimal protein dose of dual-labeled MN-14 was 10 μg per mouse, yielding a tumor-to-blood ratio of 3.5 within 72 h. The biodistribution of (111)In-DTPA-MN-14-IRDye 800CW in mice with subcutaneous LS174T tumors showed tumor uptake after 3 d (19.7% ± 17.0% injected dose/g) comparable to that of (111)In-DTPA-MN-14 but higher accumulation in the liver. The optimal time for imaging after administration of the dual-labeled antibody was 2-3 d after injection. Finally, in mice with intraperitoneally growing LS174T tumor nodules that received (111)In-DTPA-MN-14-IRDye 800CW, intraperitoneal tumor nodules could be localized with SPECT imaging after 3 d and subsequently resected using fluorescence image-guided surgery. Thus, we showed the feasibility for assessment and image-guided resection of CEA antigen-expressing tumors using dual-labeled MN-14. Both radionuclide detection and fluorescence imaging may provide useful information to improve localization of tumors and radical excision of tumor tissue. Because humanized MN-14 (labetuzumab) is available for clinical use, translation to a clinical setting is the next step.Keywords
This publication has 27 references indexed in Scilit:
- Consensus statement on the multidisciplinary management of patients with recurrent and primary rectal cancer beyond total mesorectal excision planesBritish Journal of Surgery, 2013
- Optical Image-guided Surgery—Where Do We Stand?Molecular Imaging & Biology, 2010
- A comprehensive overview of radioguided surgery using gamma detection probe technologyWorld Journal of Surgical Oncology, 2009
- What Is the Role for the Circumferential Margin in the Modern Treatment of Rectal Cancer?Journal of Clinical Oncology, 2008
- Optical Imaging: Current Applications and Future DirectionsJournal of Nuclear Medicine, 2007
- Loco-regional Recurrence from Colon Cancer: A Population-based StudyAnnals of Surgical Oncology, 2006
- Phase I Radioimmunotherapy Trial with Iodine-131—Labeled Humanized MN-14 Anti—Carcinoembryonic Antigen Monoclonal Antibody in Patients with Metastatic Gastrointestinal and Colorectal CancerClinical Colorectal Cancer, 2002
- The carcinoembryonic antigen (CEA) family: structures, suggested functions and expression in normal and malignant tissuesSeminars in Cancer Biology, 1999
- Overcoming the nephrotoxicity of radiometal-labeled immunoconjugatesCancer, 1997
- Clinical evaluation of tumor targeting with a high-affinity, anticarcinoembryonic-antigen-specific, murine monoclonal antibody, MN-14Cancer, 1993